Industry Insight
Discovery Technology
Analytical Laboratory Technology
Biopharma
Manufacturing
Delivery Systems
Ingredients, Formulation and Finishing
Bioprocessing
View our other publications with free access to extensive archives
  To print this article:
Existing subscribers please log in:
 
  USER NAME  
  PASSWORD  
   Or select

Or become a subscriber
 
 
 

Line of Sight

PET and MRI imaging techniques are beginning to enter onto the radar of the pharma industry. Kevin Cox from Imanova is sure they will become key tools in early-stage drug development decision-making, but warns that preconceptions that imaging is costly must be tackled first.

Kevin Cox, Imanova (March 2014)

Keywords: Imaging biomarkers, Positron emission tomography, Magnetic resonance imaging, Fast-to-fail strategies, Multimodal approach

    View full article    |    Back to Discovery Technology section




Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPTonline © 2004 The Pharmaceutical Technology Journal | Terms and Conditions | info@iptonline.com | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |